4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Progressive Supranuclear Palsy
Molecular NeuroImagingSmall moleculeEarly Phase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Progressive Supranuclear Palsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IOFLUPANE GE Healthcare | Phase 3 | BB |
Zoledronate California Pacific Medical Center Research Institute | Phase 4 | BB |
Riluzole King's College London | Phase 3 | B |
[18F]MNI-958 Invicro | Phase 1 | B |
Aadvac1 Adam Boxer | Phase 2 | CCC |
View all 24 →
Same molecule, other indications
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →